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Abstract
Background: The aim of this study was to assess changes in the prevalence, awareness, and treatment of 
hypertension and its effectiveness between 2007 (WOBASZ Senior study) and 2013–2014 (WOBASZ II)  
in a sample of the Polish population over the age of 75 years. 
Methods: Sampling had three stages, stratified according to voivodeships, type of community, and gen-
der. Finally, the WOBASZ II study included 467 persons (290 women and 177 men). For a comparison 
of the data, 1096 persons (538 women and 554 men) examined in the WOBASZ Senior study were used.
Results: Systolic and diastolic blood pressures significantly decreased from 153.0 ± 23.9 mmHg to 
142.9 ± 22.3 mmHg and from 85.2 ± 11.9 mmHg to 78.4 ± 11.3 mmHg, respectively, from 2007 to 2014  
(p < 0.0001). Prevalence of hypertension among people included in WOBASZ studies slightly decreased 
from 83.8% to 77.9% (rate ratio [RR]: 0.95; 95% confidence interval [CI]: 0.78–1.16) in men, and from 
75.4% to 71.8% (RR: 0.93; 95% CI: 0.8–1.09) in women. Hypertension awareness was improved from 
59.2% to 72.9% (RR: 1.23; 95% CI: 0.97–1.56) in men, and from 74,8% to 93% (RR: 1.26; 95% CI: 
1.01–1.58) in women. The proportion of men and women, with implemented hypertension treatment, 
increased from 48.4% to 61.1% (RR: 1.26; 95% CI: 1.01–1.58), and from 63.2% to 82.0% (RR: 1.3; 
95% CI: 1.1–1.53), respectively. The effectiveness of the treatment was improved over two-fold, there was 
an increase from 10.3% to 26.8% (RR: 2.65; 95% CI: 1.81–3.89) in men, and from 13.8% to 33.5% 
in women (RR: 2.44; 95% CI: 1.81–3.3). 
Conclusions: The prevalence of hypertension in Polish seniors remains high, but has decreased slightly 
in the perspective of the last 7 years. Although treatment and control has improved over the last decade, 
it remains below expectations. Efforts to improve the diagnosis and effective treatment of hypertension 
in Polish seniors should be intensified. (Cardiol J 2018; 25, 3: 333–344)
Key words: elderly, health examination surveys, clinical epidemiology, prevalence of  
hypertension, awareness of hypertension, treatment of hypertension, control of hypertension
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Introduction
Over a decade (from 2004 to 2014), the number 
of Europeans over 65 years of age has increased 
by more than 2%. In 2014, the highest percent-
age of elderly residents (over 65 years old) was 
recorded in Italy (21.4%), Germany (20.8%) and 
the lowest being Ireland (12.6%). In Poland it ac-
counted to 14.9% [1]. Between 2007 and 2014, the 
number of Poles over the age of 75 increased from 
2326423 to 2676211, which represented 6.10% and 
6.96% of the total population, respectively [2, 3]. 
The number of residents over the age of 80 will 
double to more than 3.5 million by the year 2050. 
The population of the over-80-year-olds in 2050 
will constitute 10.4% of the population nationally, 
while in 2013 it was 3.9% [4]. In the general popu-
lation in Poland, mortality due to cardiovascular 
diseases (CVD) in 2013 was approx. 46%, 53% of 
those people were over 65 years of age and over 
80% were above the age of 80 [5]. Hypertension 
is one of the most important risk factors for CVD, 
such as a coronary heart disease, heart failure and 
stroke [6]. Hypertension treatment in patients at 
a very old age, significantly reduces the incidence 
of cardiovascular events and total mortality [7–9]. 
Epidemiological studies on CVD risk factors, in-
cluding hypertension, in the elderly people are 
not frequent. Usually, an upper age limit in the 
examined populations was 74–79 years, or the data 
presented generally covered people over 65 years 
of age [10–14]. The WOBASZ study conducted 
in Poland in 2005 comprised a population below 
75 years of age [15], while the NATPOL study 
completed in 2011 included respondents below 
79 years of age [16]. Only one Polish study — 
POLSENIOR conducted in 2007–2011 involved 
a population at the age of 65–104 years [17]. In the 
present study, the prevalence, awareness, treat-
ment, and effectiveness of hypertension treatment 
in the Polish population aged 75–99 years in two 
Polish cross-sectional studies conducted in the 
years 2005–2007 and 2013–2014: WOBASZ Senior 
and using data for the age group of 75–99 years 
from WOBASZ II was examined. The changes are 
also described in systolic blood pressure (SBP) 
and diastolic blood pressure (DBP), as well as body 
mass index (BMI) and metabolic parameters such 
as the concentration of glucose, total cholesterol 
(TC), triglycerides (TG), low-density lipoprotein 
(LDL), high-density lipoprotein (HDL) in a very 
elderly Polish population. 
Methods
Study design
Data from two studies were analyzed: WOBASZ 
Senior was carried out in 2007, which included 
1096 subjects, and a subsample of 461 people 
over 74 years of age from the WOBASZ II study 
completed in 2013–2014 (WOBASZ Senior II). 
The assumptions and objectives of both projects 
as well as a detailed description of the respondents 
were described previously [18, 19]. The methodology 
(study protocol, training materials, a set of ques-
tionnaires and instructions for each element of the 
study) was based on protocol of the first edition of 
WOBASZ [20] and European Union guidelines con-
cerning the methodology of epidemiological studies 
of CVDs (EHES) [21]. The examined sample was 
randomly selected from the Polish population, at 
the Department of National Registers MIA (an elec-
tronic register — PESEL). The selection was made 
separately in each voivodeship. A schematic diagram 
of sampling was three-stage, stratified according to 
voivodeship, category of municipalities, and sex.
Data collection and measurement
The participants were stratified into the fol-
lowing three age groups: 75 to 79, 80 to 84, and 
85 years.  Subsequent to overnight fasting, blood 
specimens were obtained for the measurement of 
serum lipids and glucose, and the samples were 
sent to a central certified laboratory (Diagnostyka 
Sp. z o.o., Warsaw, Poland) [19]. BMI was calculated 
as the ratio of weight (kg) and height squared (m). 
The following definitions were accepted:
 — obesity — when BMI ≥ 30 kg/m2;
 — diabetes — when diagnosed previously or if 
the patient received hypoglycemic drugs;
 — hyperlipidemia — when TC level exceeded 5.0 
mmol/L or cholesterol LDL exceed 3.0 mmol/L 
or if the patient received lipid-lowering drugs;
 — coexisting CVD — previously diagnosed coro-
nary artery disease, past myocardial infarction, 
myocardial revascularization, previous stroke, 
peripheral atherosclerosis;
 — education — the participants were divided into 
two groups — less than 7 years of education 
or 7 years and more;
 — physical activity — at least 30 min of uninter-
rupted activity, e.g.: a walk, gymnastic exer-
cises at least once a month;
 — smoking — at least one cigarette per day over 
the last year;
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 — marital status — married or widow/widower, 
single. 
Blood pressure measurement and definitions
Blood pressure (BP) measurements were per-
formed as recommended by ESC/ESH 2013 [22]. 
Pressure measurements took place in one visit, in 
a quiet room in a sitting position with back propped. 
Participants did not drink coffee or smoke ciga-
rettes for a minimum 30 min before measurement. 
Automatic devices approved by the Association 
for the Advancement of Medical Instrumentation 
(AAMI) were used for the measurements: AND 
UA-767 in WOBASZ Senior study, and AND UA-631 
in WOBASZ II study (AND Company Limited, 
Tokyo, Japan). The measurement was performed 
3 times at 1 min intervals on the right shoulder in 
a sitting position, after a 5 min rest. An average 
value from the second and third measurement was 
taken for pressure evaluation. If all three pressure 
measurements were not completed, a single meas-
urement or an average of two measurements were 
taken into account.
According to the recommendations of the 
World Hypertension League Expert Committee 
[23], the following definitions were accepted:
 — hypertension was calculated as the proportion 
of participants presenting SBP ≥ 140 mmHg or 
DBP ≥ 90 mmHg or reports currently (regu-
lar in last 2 weeks) treatment for high BP, to 
whole sample;
 — proportion of awareness of hypertension was 
calculated as the proportion of participants 
with hypertension who report either being 
diagnosed with hypertension by a health pro-
fessional or report taking medication for high 
BP, to hypertensive patients; (affirmative re-
sponse to the questions: “Have you ever been 
told by a doctor that you had hypertension, 
also called high blood pressure?” and “Have 
you ever taken medicine prescribed because 
of high blood pressure?”;
 — the proportion of treated hypertension was cal-
culated as the proportion of participants with 
hypertension who report taking medication 
for high BP, to all hypertensive participants 
(affirmative response to the questions: “Have 
you taken this medicine regularly during the 
last 2 weeks?”;
 — proportion of controlled hypertension was 
calculated as the proportion of participants 
with hypertension, who both: reported taking 
medication for high BP and had SBP < 140 
mmHg and DBP < 90 mmHg, to all hyperten-
sive participants. Due to the fact that European 
and Polish guidelines allow in people over 80 
years old an exception to the determined tar-
get pressure (BP < 140/90 mmHg), additional 
calculations were made for the threshold of 
150/90 mmHg.
The described BP categories (optimal, normal 
and high normal) concerned the whole population, 
including those treated. However, the same metho-
dology in the presentation of results was adopted 
for a previous publication on the WOBASZ study. 
Owing to this the obtained results could be com-
pared and evaluated for changes in the prevalence 
of raised BP in the Polish population.
The subjects were qualified for the optimal 
pressure group according to the recommendations 
of PTNT 2015 [19] and ESC/ESH 2013 [22], when 
SBP < 120 mmHg and DBP < 80 mmHg, for the 
normal pressure group when SBP was 120–129 
mmHg and/or DBP 80–84 mm Hg and for high-
normal group, when SBP was 130–139 mmHg and/ 
/or DBP 85–89 mmHg. Grade 1 hypertension was 
diagnosed when SBP was 140–159 mmHg and/ 
/or DBP 90–99 mm Hg, grade 2 when SBP was 
160–179 mmHg and/or DBP 100–109 mmHg, grade 
3 when SBP was ≥ 180 mmHg and/or DBP ≥ 110 
mmHg. Isolated systolic hypertension was diag-
nosed as SBP ≥ 140 mm Hg and DBP < 90 mmHg.
Statistical analysis
All statistical tests were two-sided and sta-
tistical significance was accepted for p < 0.05. Pa-
rameters such as BP values were described using 
an arithmetic mean and standard deviation. Crude 
incidence of hypertension, awareness, frequency 
of treatment, BP control (as defined above) were 
described as percentages, with standard error and 
95% confidence interval (95% CI) at the following 
age intervals: 75–79, 80–84 and over 85 years. The 
results were standardized [24] for age and sex of 
the Polish population on the basis of data from the 
report of the Central Statistical Office of 31.12.2014 
(Suppl. Tables 1 and 2) [25]. 
The rate ratio (RR) with 95% CI was calcu-
lated, dividing the standardized frequency of above 
listed parameter in WOBASZ II and WOBASZ 
Senior study, in order to evaluate the changes in 
the prevalence of optimal, normal, high-normal 
pressure, grade 1, 2 and 3 hypertension, isolated 
systolic hypertension, and awareness, treatment 
and control of hypertension between WOBASZ 
Senior and WOBASZ II studies. RR value lower 
than 1.0 indicates, with statistical significance, 
a decreased prevalence, while above 1.0 — an 
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increased one. A logistic regression was used to 
calculate the factors associated with awareness, 
treatment and control of hypertension in the 2007 
and 2014 surveys. The statistical analysis was per-
formed using Statistica 12.5 (StatSoft Inc., Tulsa, 
Oklahoma, United States). 
Results
WOBASZ Senior and WOBASZ II studies 
included 1096 and 467 patients at the age of over 
74 years, respectively. The characteristics of the 
study samples is shown in Tables 1 and 2. 
The mean age of participants was 79.1 ± 3.7 
years in 2007 and significantly increased to 80.1 ± 
± 4.1 years in 2014 (p < 0.0001). The proportion 
of participants aged 75 and older rapidly increased 
over the 7 years, which indicative of the aging 
population. 
The number of married seniors and education 
level increased significantly. The number of men 
who declared minimum 30-min, uninterrupted ef-
fort at least once a month, decreased significantly. 
SBP and DBP significantly decreased from 153.0 ± 
± 23.9 mmHg to 142.9 ± 22.3 mmHg and 85.2 ± 
± 11.9 mmHg to 78.4 ± 11.3 mmHg, respectively, 
from 2007 to 2014 (p < 0.0001). A significant de-
crease in mean SBP and DBP was observed in the 
all analyzed age and sex groups. There was also 
a significant reduction in the level of TC and 
LDL, from 5.0 ± 1.1 mmol/L to 4.9 ± 1.2 mmol/L 
(p < 0.0001) and from 3.4 ± 1.0 mmol/L to 3.0 ± 
± 1.0 mmol/L (p < 0.0001), respectively. An in-
crease in the mean fasting plasma glucose from 5.6 ± 
± 2.1 mmol/L to 6.0 ± 1.5 mmol/L (p = 0.0004) was 
noted (Table 1). The results are presented in Table 3.
Prevalence of optimal, normal, high-normal 
BP, isolated systolic hypertension and 
grades 1, 2 and 3 hypertension
The prevalence of optimal pressure in Polish 
population aged 75–99 years (after standardiza-
tion for age and sex) significantly increased from 
2007 to 2014 in both men and women, from 4.9% 
to 14.7% (RR: 3.08; 95% CI: 1.81–5.26) and 4.7% 
to 10% (RR: 2.04; 95% CI: 1.19–3.5), respectively. 
Also, frequency of normal pressure increased from 
10.3% to 15.3% (RR: 1.49; 95% CI: 0.94–2.35) 
and from 8.1% to 19.7% (RR: 2.43; 95% CI: 1.64– 
–3.61). There were no significant differences in 
the prevalence of high-normal BP, isolated systolic 
hypertension grade 1 hypertension and grade 2 
hypertension. Frequency of grade 3 hypertension 
decreased from 12.7% to 6.3% (RR: 0.5; 95% CI: 
0.26–0.93) and from 19.8% to 5.3% (RR: 0.27; 95% 
CI: 0.16–0.46) (Fig. 1; Suppl. Table 3a, b). 
Prevalence, awareness, treatment  
and control of hypertension
Prevalence of hypertension among people in-
cluded in WOBASZ Senior and WOBASZ II studies 
decreased from 75.4% to 71.8% (RR: 0.93; 95% CI: 
0.8–1.09) in men, and from 75.4% to 71.8% (RR: 
0.93; 95% CI: 0.8–1.09) in women. Hypertension 
awareness was improved from 59.2% to 72.9% 
(RR: 1.23; 95% CI: 0.97–1.56) in men, and 74.8% to 
93% (RR: 1.26; 95% CI: 1.01–1.58) in women. The 
proportion of men and women, with implemented 
hypertension treatment, increased from 48.4% to 
61.1% (RR: 1.26; 95% CI: 1.01–1.58), and from 
63.2% to 82.0% (RR: 1.3; 95% CI: 1.1–1.53), re-
spectively. The effectiveness of the treatment (for 
hypotensive target < 140/90 mmHg) was improved 
over two-fold, there was an increase from 10.3% to 
26.8% (RR: 2.65; 95% CI: 1.81–3.89) in men, and 
from 13.8% to 33.5% in women (RR: 2.44; 95% CI: 
1.81–3.3). Similarly the effectiveness of the treat-
ment (for hypotensive target < 150/90 mmHg in 
people > 80 years old) was improved over two-fold 
from 14.5% to 32.4% (RR: 2.23; 95% CI: 1.59–3.14) 
in men, and from 18.9% to 42.0% in women (RR: 
2.22; 95% CI: 1.81–2.89).
The highest prevalence of hypertension be-
tween 2007 and 2014 was observed in people over 
the age of 85. The highest awareness of hyperten-
sion was recorded in the WOBASZ Senior study in 
patients aged 75–79, and in the WOBASZ II study 
in patients between 80 and 84 years of age. Simi-
larly, the highest percentage of patients in 2007 
was treated in the population aged 75–79, and in 
2014 this concerned patients at the age of 80–84. 
In 2007, the best pressure control was found in 
patients aged 80–84, and in 2014 in patients in 
9th and 10th decade of life (Fig. 2; Suppl. Table 4).
A logistic regression model was performed to 
show how age, sex, obesity, coexisting diabetes, 
hyperlipidemia and other CVD, as well as the 
level of education, physical activity, smoking and 
marital status, affect an awareness, treatment and 
control of hypertension in WOBASZ Senior and 
WOBASZ II studies. Female sex, other CVD and 
smoking, both in 2007 and 2014, were significantly 
correlated with awareness, treatment and hyper-
tension control. In the year 2007, obesity and low 
level of education significantly affected the aware-
ness of the investigated disease and its treatment. 
Similarly, coexisting diabetes affected hypertension 
treatment and control. Marital status significantly 
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affected hypertension awareness in 2007. Table 4 
shows factors affecting awareness, treatment and 
control of hypertension in 2007 and 2014 in the 
elderly Polish population.
Discussion
According to available research, this is the 
first study presenting the changes in trends over 
Table 1. Characteristic of subjects in WOBASZ Senior and WOBASZ Senior II Study.
WOBASZ Senior (2005–2007) WOBASZ Senior II (2013–2014)
n % 95% CI n % 95% CI P
75–79 691 63.1 59.5–66.7 244 47.8 41.2–54.3 < 0.00001
Men 370 66.8 62.1–71.6 95 46.3 35.5–57.1 < 0.00001
Women 321 59.3 54.0–64.7 149 48.6 40.4–56.9 0.0310
80–84 306 28.0 23.0–33.0 144 30.8 23.3–38.4 0.2633
Men 130 23.4 16.1–30.7 56 31.6 19.5–43.8 0.0291
Women 176 32.7 25.8–39.6 26 30.3 20.7–40.0 0.4791
≥ 85 95 8.7 3.0–14.3 149 16.9 8.6–25.2 < 0.00001
Men 54 9.7 1.8–17.6 88 14.7 1.1–28.3 0.6500
Women 41 7.6 0–15.7 53 18.3 7.9–28.7 < 0.00001
Age  
standardized
95% CI Age  
standardized
95% CI P
Obesity 320 26.4 23.1–29.7 143 28.8 23.9–33.6 0.6558
Men 121 20.3 16.4–24.2 42 22.4 15.6–29.2 0.1505
Women 199 31.8 26.7–36.9 101 32.7 26.2–39.3 0.3992
Diabetes 200 17.5 14.7–20.3 100 21.5 17.1–25.8 0.0194
Men 92 15.6 12.1–19 36 20.5 13.7–27.3 0.2146
Women 108 20.5 15.6–25.5 64 22.0 16.4–27.6 0.0657
Hyperlipidemia 713 64.2 58.7–69.7 302 64.2 56.7–71.6 0.9012
Men 340 59.3 52.5–66.2 108 60.2 48.7–71.7 0.7435
Women 373 70.5 61.5–79.5 194 66.8 57.1–76.4 0.7975
Diagnosed CVD 611 56.3 51.1–61.4 247 54.0 47–60.9 0.0084
Men 288 52.9 46.2–59.5 94 53.6 42.6–64.5 0.5048
Women 323 59.4 51.4–67.3 153 54.3 45.4–63.2 0.0027
Education  
≥ 7 years
476 39.0 35–43 433 91.9 83–100 < 0.00001
Men 388 65.9 58.8–73 170 96.1 81.4–100 < 0.00001
Women 88 12.7 9.9–15.6 263 89.3 78.2–100 < 0.00001
Physical exercise  
≥ 30/min
466 37.3 45.1–66.4 150 30.5 25.6–35.5 0.0773
Men 283 46.1 40.3–51.9 62 34.8 26–43.6 0.0255
Women 183 29.8 24.6–35 88 27.9 21.9–33.8 0.9401
Smokers 87 6.7 5.1–8.2 34 6.8 4.5–9.2 0.4883
Men 69 10.8 8.1–13.5 26 14.1 8.6–19.5 0.1521
Women 18 3.0 1.3–4.7 8 2.7 0.8–4.6 0.7
Marital status 295 28.6 24.8–32.5 274 59.0 51.9–66.2 < 0.00001
Men 115 21.9 17.5–26.3 90 51.6 40.8–62.4 0.0004
Women 180 36.2 29.5–43 184 63.2 53.8–72.6 < 0.00001
CVD — cardiovascular disease; CI — confidence interval
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2007–2014, in the range of prevalence of optimal, 
normal, high-normal pressure, isolated systolic 
hypertension and grade 1 and 2 hypertension, as 
well as the degree of awareness, treatment and 
control of hypertension in the very elderly Polish 
population. The only Polish epidemiological study 
on the elderly and very elderly population involv-
ing 4950 people at the age of 65–104 years, was 
PolSenior study [26], carried out between 2007 and 
2011. Comparing WOBASZ Senior, PolSenior and 
WOBASZ II studies, a gradual decrease was found 
in average SBP and DBP in both men and women. 
In these observations, the number of seniors with 
optimal and normal BP increased significantly, and 
the number of patients with grade 1 and 2 hyper-
tension decreased. This can be explained  by an 
increase in the number of patients treated with 
antihypertensive drugs, and an increase in the 
number of patients who managed to improve BP 
control. These data are consistent with the global 
trend for the general population, in which a decline 
in both SBP and DBP has been observed in recent 
Table 2. Clinical characteristic of subjects who completed both the WOBASZ Senior and WOBASZ II 
surveys.
WOBASZ Senior (2003–2005) WOBASZ II (2013–2014)  
under 74 years
n Mean SD 95% CI n Mean SD 95% CI P
Whole population
Age [years] 1096 79.1 3.7 78.9–79.3 467 80.1 4.1 75–99 < 0.0001
SBP [mmHg] 1092 153.0 23.9 151.6–154.4 467 142.9 22.3 84–228.5 0.20690
DBP [mmHg] 1078 27.9 5.2 27.6–28.2 426 28.1 4.7 17.7–43.5 < 0.0001
BMI [kg/m2] 1092 85.2 11.9 84.5–85.9 467 78.4 11.3 46–150 < 0.0001
TC [mmol/L] 929 5.2 1.1 5.1–5.2 434 4.9 1.2 1.9–8.8 < 0.0001
TG [mmol/L] 928 1.3 0.7 1.3–1.4 434 1.4 0.7 0.4–5.4 0.0142
LDL [mmol/L] 929 3.4 1.0 3.3–3.4 434 3.0 1.0 0.8–6.6 < 0.0001
HDL [mmol/L] 929 1.4 0.4 1.3–1.4 434 1.4 0.4 0.4–2.9 NA
FPG [mmol/L] 950 5.6 2.1 5.5–5.8 435 6.0 1.5 3.7–14.6 0.0004
Men
Age [years] 555 79.0 3.9 78.7–79.3 177 79.9 4.2 79.3–80.6 0.089
SBP [mmHg] 554 151.0 23.2 149.1–153 177 141.0 22.3 137.7–144.3 < 0.00001
DBP [mmHg] 545 27.1 4.2 26.8–27.5 165 27.3 4.4 26.6–28 0.5856
BMI [kg/m2] 554 83.7 11.4 82.8–84.7 177 77.3 12.9 75.4–79.2 < 0.00001
TC [mmol/L] 471 4.9 1.0 4.9–5 169 4.8 1.3 4.6–5 0.3053
TG [mmol/L] 471 1.2 0.6 1.1–1.2 169 1.4 0.7 1.3–1.5 0.6658
LDL [mmol/L] 471 3.2 1.0 3.1–3.3 169 2.9 1.1 2.8–3.1 0.0012
HDL [mmol/L] 471 1.3 0.4 1.3–1.3 169 1.3 0.4 1.3–1.4 ND
FPG [mmol/L] 481 5.6 2.1 5.4–5.7 170 6.0 1.4 5.8–6.2 0.0213
Women
Age [years] 541 79.2 3.4 78.9–79.5 290 80.1 4.1 79.7–80.6 0.0008
SBP [mmHg] 538 154.9 24.5 152.9–157 290 144.1 22.2 141.6–146.7 < 0.00001
DBP [mmHg] 538 86.7 12.2 85.7–87.7 290 79.1 10.1 77.9–80.2 < 0.00001
BMI [kg/m2] 533 28.8 5.9 28.3–29.3 261 28.6 4.7 28–29.2 0.6326
TC [mmol/L] 458 5.4 1.1 5.3–5.5 265 5.0 1.2 4.9–5.1 < 0.00001
TG [mmol/L] 457 1.5 0.7 1.4–1.6 265 1.5 0.7 1.4–1.6 ND
LDL [mmol/L] 458 3.5 1.1 3.4–3.6 265 3.0 1.0 2.9–3.1 < 0.00001
HDL [mmol/L] 458 1.4 0.4 1.4–1.4 265 1.4 0.4 1.4–1.5 ND
FPG [mmol/L] 469 5.7 2.1 5.5–5.9 265 6.0 1.6 5.8–6.2 0.044
BMI — body mass index; CI — confidence interval; DBP — diastolic blood pressure; FPG — fasting plasma glucose; HDL — high density  
lipoprotein cholesterol; LDL — low density lipoprotein cholesterol; SBP — systolic blood pressure; SD — standard deviation; TC — total  
cholesterol; TG — triglicerydes
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years [27]. In populations of seniors, hypertension 
is more common in women. This was confirmed 
by American (NHANES) [28] and German studies 
(CARLA-STUDY) [29]. 
Prevalence of hypertension observed in the 
analyzed groups of seniors participating in WOBSZ 
Senior and WOBASZ Senior II studies was similar 
to populations of developed countries of Western 
Europe, e.g. France and Germany (comparison of 
the incidence of hypertension, awareness, treat-
ment and control is presented in Suppl. Table 5). 
The prevalence of hypertension in Poland is 
slightly higher than in the American, Greek, 
Italian, Spanish and Thai populations. These stud-
ies consistently show a higher incidence of hyper-
tension in women compared to men. A similar trend 
was observed in the American and German studies 
— higher hypertension awareness and treatment 
Table 3. Crude mean systolic blood pressure in WOBASZ Senior and WOBASZ Senior II in population 
at the age 75–99. 
WOBASZ Senior (2005–2007) WOBASZ Senior II (2013–2014)
n Mean SD 95% CI n Mean SD 95% CI P
SYSTOLIC BLOOD PRESSURE
Overall
75–79 691 152.6 23.9 150.8–154.4 244 143.2 22.2 140.4–146.0 < 0.00001
80–84 306 152.6 23.3 149.1–157.2 144 140.3 22.3 139.4–146.8 < 0.00001
≥ 85 95 156.9 25.6 151.7–162.1 79 141.8 22.3 136.8–146.8 0.0001
Total 1092 153.0 23.9 151.6–154.4 467 142.9 22.3 140.9–145.0 < 0.00001
Men
75–79 370 150.1 23.1 147.7–152.4 95 140.4 22.1 135.9–144.9 0.0003
80–84 130 153.2 23.3 148.8–155.7 56 139.4 23.2 137.5–149.6 0.02
≥ 85 54 152.7 23.4 146.3–159.1 26 137.7 22.7 128.5–146.8 0.082
Total 554 151.0 23.2 149.1–153.0 177 141.0 22.3 137.7–144.3 < 0.00001
Women
75–79 321 155.5 24.5 152.8–158.2 149 145.0 22.1 141.4–148.6 0.0065
80–84 176 152.2 23.4 148.8–155.7 88 141.1 21.8 138.0–147.6 0.0048
≥ 85 41 162.3 27.5 153.6–171.0 53 143.8 22.1 137.8–150.0 0.0005
Total 538 154.9 24.5 152.9–157.0 290 144.1 22.2 141.6–146.7 < 0.00001
DIASTOLIC BLOOD PRESSURE
Overall
75–79 691 85.4 11.9 84.5–86.3 244 78.8 11.6 77.3–80.2 < 0.00001
80–84 306 85.2 11.9 83.8–86.5 80 78.2 12.1 76.4–80.1 < 0.00001
≥ 85 95 84.0 11.8 81.6–86.4 79 77.5 10.8 75.0–79.9 0.0002
Total 1092 85.2 11.9 84.5–86.0 467 78.4 11.3 77.4–79.4 < 0.00001
Men
75–79 370 83.6 11.4 82.4–84.8 95 78.8 13.8 76.0–81.6 0.0005
80–84 130 84.4 11.2 82.5–86.3 36 75.5 12.9 73.6–80.0 0.0001
≥ 85 54 82.9 11.4 79.7–86.0 26 72.7 10.8 68.3–77.0 0.0003
Total 554 83.7 11.4 82.8–84.7 177 77.3 12.9 75.4–79.2 < 0.00001
Women
75–79 321 87.4 12.1 86.1–88.7 149 78.7 9.9 77.1–80.3 < 0.00001
80–84 176 85.7 12.4 83.9–87.6 44 80.5 11.0 77.0–81.4 < 0.00001
≥ 85 41 85.5 12.4 81.6–89.4 53 79.8 10.1 77.0–82.6 0.0159
Total 538 86.7 12.2 85.7–87.7 290 79.1 10.1 77.9–80.2 < 0.00001
CI — confidence interval; SD — standard deviation
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Figure 1. Changes in the prevalence of blood pressure (BP) classes i.e. optimal, normal, high normal BP, grades 1, 2 
and 3 hypertension (HT) and isolated systolic hypertension (ISH) in a subsample at ages restricted to 75–99 years in 
WOBASZ Senior (2005–2007) and WOBASZ II (2013–2014); M — men; W — women.
Figure 2. Changes in the hypertension prevalence, awareness, treatment, and control of blood pressure in a sub-
sample at ages restricted to 75–99 years in WOBASZ Senior (2005–2007) and WOBASZ II (2013–2014); M — men; 
W — women.
were observed in more women than in men. An 
effectiveness of hypertension treatment is higher 
in women than in men, regardless of the examined 
senior population. Comparing the WOBASZ studies 
to another Polish POLSENIOR study, it was noted 
that an increase in hypertension prevalence in Pol-
ish seniors population with a concurrent increase 
in the frequency of its awareness. Also observed 
was a systematic increase in the number of patients 
with implemented hypertension treatment, with 
simultaneous improvement in its effectiveness. 
The control of arterial pressure in the elderly 
is important because, as recently described by 
Piotrowicz et al. [30], it may correlate with mood 
disorders and cognitive impairment.
While the awareness and frequency of hy-
pertension treatment in the Polish senior popula-
tion, which is similar to values observed in the 
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inhabitants of developed countries in America 
and Western Europe, the pressure control is over 
two-fold worse. 
Potential impact of the 2017 ACC/AHA guide-
lines on prevention and treatment of hyperten-
sion in the Polish population needs to be further 
evaluated in future. The analysis of epidemiological 
data on the American population has shown that 
a percentage of American adults meeting the defini-
tion for hypertension according to the 2017 ACC/ 
/AHA guideline [31] and the JNC7 [32] guideline 
based on the 2011–2014 NHANES in people over 
75 years old was 82.3% and 75.1%, respectively. 
A percentage of American adults with SBP of 130 to 
139 mmHg or DBP of 80 to 89 mm Hg are recom-
mended for antihypertensive medication according 
to the 2017 ACC/AHA guideline in people over 75 
was 100% [33].
A significant decline in physical activity among 
the seniors over less than a decade can be consid-
ered as a worrisome tendency. Also, a significant 
increase in hyperlipidemia prevalence in the Pol-
ish elderly examined in WOBASZ Senior and 
WOBASZ II studies is an issue. An increase in 
the incidence of obesity and diabetes also raises 
concern. Similar changes, although smaller, were 
also observed in the Polish population aged 20– 
–75 years in the decade 2003/4–2013/14 [34–36] 
and in the study by Jarosz et al. [37]. It was re-
ported in a number of studies, similarly to the pre-
sent observations, that females significantly affect 
an increased hypertension awareness, treatment 
and control [38–41]. A similar relationship was 
also confirmed for obesity. This is consistent with 
a study conducted by He et al. [42]. In turn, 
another study demonstrated that obesity was 
significantly related to higher awareness and 
worse pressure control [38–40, 43]. In WOBASZ 
Senior and WOBASZ Senior II studies, smoking 
significantly affected lower awareness and treat-
ment frequency and blood pressure control. This 
is consistent with other observations [44–46]. 
The coexistence of other CVD and diabetes 
significantly increased the awareness of hyper-
tension in the Polish study conducted among 
seniors. Comparable results were obtained in 
a Chinese population over the age of 60 [38]. The 
relationship between education level and hyper-
tension awareness, treatment and control varies 
depending on the population analyzed. WOBASZ 
Senior study demonstrated a significant relation-
ship between low levels of education and lower 
awareness and lower incidence of hypotensive 
treatment, as in the Chinese population, the 
study conducted by Wu et al. [40], Tian et al. [45], 
and Chiu [46]. In turn, higher education in the 
study by Wang et al. [47] was associated with lower 
awareness and less frequent treatment.
One, strength of the WOBASZ studies is the 
large group of people examined — of 2007, n = 1096 
and of 2013/14, n = 461. Second, sampling was 
performed in three stages, stratified according 
to voivodeship, type of community, and gender. 
The findings in the present study are subjected to 
some limitations. First, the study design assumed 
BP measurements on only one visit. Therefore, 
the results may overestimate the prevalence of 
hypertension and underestimate of its control. 
Second, because the described categories of BP 
concerned the whole population, including those 
treated, obtained rates of optimal, correct and high 
optimal pressure could be overestimated. 
Conclusions
In the years 2007–2014, SBP and DBP sig-
nificantly decreased in people aged 75 years and 
older. Prevalence of hypertension in the Polish 
senior population slightly decreased, while aware-
ness, frequency of treatment and disease control 
improved. Despite a significant increase in hyper-
tension control in Poland in the elderly, during the 
7-year observation period, approx. 70% of seniors 
present poorly in controlled pressure. 
This results should mobilize both primary 
care physicians and specialists to increase efforts 
to intensify antihypertensive treatment in this 
group of patients.
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